Robert W. Baird Upgrades Teladoc Health (TDOC) to Outperform

Share on StockTwits

Teladoc Health (NYSE:TDOC) was upgraded by Robert W. Baird from a “neutral” rating to an “outperform” rating in a report issued on Monday, The Fly reports. The analysts noted that the move was a valuation call.

Other equities analysts also recently issued research reports about the company. upped their target price on Teladoc Health from $68.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, September 28th. Cantor Fitzgerald upped their target price on Teladoc Health from $52.00 to $83.00 and gave the company a “neutral” rating in a report on Friday, September 28th. They noted that the move was a valuation call. Citigroup reiterated a “buy” rating and issued a $95.00 target price on shares of Teladoc Health in a report on Friday, September 28th. Piper Jaffray Companies boosted their price target on Teladoc Health to $84.00 and gave the company an “overweight” rating in a research note on Friday, September 21st. Finally, KeyCorp boosted their price target on Teladoc Health from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teladoc Health presently has an average rating of “Buy” and a consensus price target of $83.42.

NYSE TDOC opened at $55.47 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.99 and a current ratio of 8.99. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -33.62 and a beta of 1.21. Teladoc Health has a 1 year low of $30.88 and a 1 year high of $89.05.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $111.00 million for the quarter, compared to the consensus estimate of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The firm’s quarterly revenue was up 61.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.55) EPS. On average, sell-side analysts expect that Teladoc Health will post -1.48 earnings per share for the current year.

In other news, insider Adam C. Vandervoort sold 5,500 shares of the stock in a transaction that occurred on Tuesday, January 8th. The stock was sold at an average price of $53.80, for a total value of $295,900.00. Following the completion of the sale, the insider now directly owns 2,934 shares of the company’s stock, valued at $157,849.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $70.29, for a total value of $1,757,250.00. Following the completion of the sale, the chief executive officer now directly owns 511,184 shares of the company’s stock, valued at $35,931,123.36. The disclosure for this sale can be found here. Insiders have sold 208,683 shares of company stock valued at $12,872,473 in the last ninety days. Company insiders own 3.95% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Harvest Fund Management Co. Ltd bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $165,000. Signaturefd LLC bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $173,000. D.A. Davidson & CO. bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $210,000. National Asset Management Inc. bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $224,000. Finally, Ibex Investors LLC bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $224,000.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Mutual Funds

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply